Cytosorbents Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
4,677.80
9,321.70
8,131.70
11,763.50
8,460.80
17,211.20
Depreciation, Depletion & Amortization
64.40
65.50
113.00
161.60
218.30
390.60
Other Funds
826.70
3,197.20
576.60
3,210.70
1,942.40
6,918.70
Funds from Operations
3,786.70
6,058.90
8,595.30
8,391.10
6,300.10
9,901.90
Changes in Working Capital
297.40
602.30
413.60
1,660.10
160.60
937.80
Net Operating Cash Flow
3,489.30
6,661.20
9,008.90
6,731.00
6,460.70
10,839.70
Capital Expenditures
216.40
367.30
643.40
595.50
1,678.10
Purchase/Sale of Investments
-
1,944.50
247.50
2,192.00
-
Net Investing Cash Flow
216.40
2,311.90
890.90
1,596.50
1,678.10
Issuance/Reduction of Debt, Net
-
-
-
4,881.20
4,998.40
Net Financing Cash Flow
4,202.70
10,016.90
11,640.20
5,064.20
20,123.10
Net Change in Cash
453.70
1,422.30
1,711.60
71.70
12,076.70
Free Cash Flow
3,528.00
6,814.40
9,412.50
6,871.70
7,451.40
Change in Capital Stock
2,359.70
10,016.90
11,640.20
183.00
15,124.60
Exchange Rate Effect
43.30
378.40
28.80
1.40
92.40

About Cytosorbents

View Profile
Address
7 Deer Park Drive
Monmouth Junction New Jersey 08852
United States
Employees -
Website http://cytosorbents.com
Updated 07/08/2019
CytoSorbents Corp. engages in the development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product, CytoSorb, is a extracorporeal cytokine filter and seeks to reduce cytokine storm that could otherwise cause massive inflammation, organ failure, and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.